Pregnancy: Teratogenic Effects- Pregnancy Category B: Cefepime was not teratogenic or embryocidal when administered during the period of organogenesis to rats at doses up to 1000 mg/kg/day (4 times the recommended maximum human dose calculated on a mg/m2 basis) or to mice at doses up to 1200 mg/kg (2 times the recommended maximum human dose calculated on a mg/m2 basis) or to rabbits at a dose level of 100 mg/kg (approximately equal to the recommended maximum human dose calculated on a mg/m2 basis). There are, however, no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers: Cefepime is excreted in human breast milk in very low concentrations [0.5 mcg/mL]. Caution should be exercised when cefepime is administered to a nursing woman.
Labor and Delivery: Cefepime has not been studied for use during labor and delivery. Treatment should only be given if clearly indicated.